Guangzhou-Based Aysun Medical Secures Angel Funding to Advance Small-Diameter Vascular Grafts

Jun 02, 2025 16:30 CST Updated 16:30

AERSUN

High-end Implantable Medical Device Product Developer

Recently,AERSUN (Guangzhou) Biotechnology Co., Ltd.(hereinafter referred to as "AERSUN") announced the completionAngel Round FinancingThis round of financing was exclusively invested by Daotong Investment. The funds will mainly be used for the clinical advancement of small-caliber artificial blood vessels and the development of extended applications of core technologies.

AERSUNFounded in 2023, headquartered in Guangzhou, it is a company focused on the development, production, and sales of high-end implantable medical device products. The company has professional R&D and manufacturing capabilities in the field of tissue repair and reconstruction, andWuhan University of TechnologyAnd has established in-depth cooperative relationships with clinical medical experts in China, dedicated to promoting the integration of medicine and engineering, and打通产学研医产业链条.

The core product of AERSUN isSmall-Caliber Artificial Blood Vessel. This product is developed using the company's proprietary technology to address pain points in clinical applications. The company has built a Class 10,000 GMP workshop and advanced laboratories in the ZHONGCHUANG Health Industrial Park in Jiangxia District, Wuhan, forming capabilities in research and development, production, and testing, while promoting clinical trials of small-diameter artificial blood vessels. The artificial blood vessel market has long been monopolized by imported products, and AERSUN’s products are expected toConstruction of Vascular Access for Hemodialysis, Coronary Artery Bypass GraftingProvide higher-quality solutions in scenarios such as...

April 29, 2025AERSUNSuccessfully CompletedThe FirstChinese-Made Ready-to-Use Artificial Blood VesselsTheFirst Patient Clinical Trial Implantation。

The characteristics of this artificial blood vessel areReady-to-wear Design, allowing puncture dialysis within three days after surgery, significantly shortening the waiting time for patients to begin dialysis. Compared with traditional artificial blood vessels, which usually require 4-8 weeks for swelling to subside before dialysis can be performed, AERSUN's product demonstrates significant advantages in long-term patency, tolerance to repeated punctures, and ease of surgical suturing.

▲Source of the article:SiYu Medtech

▲Please indicate the above source for reprinting.

Disclaimer: This article is intended solely for the purpose of information transmission and is for reference only. It does not constitute any advice on investment or treatment; please evaluate carefully. If it involves issues related to the content, copyright, or other aspects of the work, to ensure the rights and interests of both parties, please contact us and we will handle it immediately. If any platform reprints this article, it must take responsibility for the content itself; the Medical Device Innovation Network is not responsible for any secondary dissemination caused by the reprint.

PAST/ISSUE/REVIEW

GE Major Personnel Changes, The new president will take office on "May Day"!

Giant Chaos! Who Can Take Down the BD200 Billion "Big Cake"?

Rolling in Tears, United Imaging Bags Another 113 Million Yuan Mega Contract!